Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Blackstone Inc (BX) Price & Performance

Amgen, Inc.Trade
Blackstone IncTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Blackstone Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Blackstone Inc trades at $147.89 (market cap $117.44B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Blackstone Inc pays the higher dividend (3.55%). Which is the better fit depends on your goals.

AMGNBX
Market Cap
$224.14B$117.44B
Sector
HealthFinancials
52-Week High
$417.20$188.68
52-Week Low
$271.18$102.12
Enterprise Value
$267.45B
Dividend Yield
2.43%3.55%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Blackstone Inc

Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.

Read more on BX